Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.

A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

Disclosed are methods for treating human immunodeficiency virus (HIV) or AIDS in a human subject using only two antiretroviral drugs, the subject being virologically suppressed and having previously followed a treatment regimen including at least three antiretroviral drugs.

Disclosed are methods for treating human immunodeficiency virus (HIV) or AIDS in a human subject using only two antiretroviral drugs, the subject being virologically suppressed and having previously followed a treatment regimen including at least three antiretroviral drugs.

Disclosed are methods for treating human immunodeficiency virus (HIV) or AIDS in a human subject using only two antiretroviral drugs, the subject being virologically suppressed and having previously followed a treatment regimen including at least three antiretroviral drugs.

Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.

Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.

The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

A method for treating a malignant tumor of a human patient, the method comprising administering trans-3-amino-1-methyl-3-(4-(3-phenyl-5H-imidazo[1,2-c]pyrido[3,4-e][1,3]oxazin-2-yl)phenyl)cyclobutanol (Compound 1) or a salt thereof to a patient in need of the treatment according to an administration schedule in which the Compound 1 or a salt thereof is administered in a dose of 4 mg/body/day to 160 mg/body/day in tams of Compound 1 for 4 consecutive days, followed by a prescribed withdrawal period of 3 days.